Download presentation
Presentation is loading. Please wait.
Published byCharlene Elliott Modified over 5 years ago
1
Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1 Omar Abdel-Razek, MD, Singh N. Sadananda, PhD, Xuan Li, MSc, Lubomira Cermakova, MSc, Jiri Frohlich, MD, FRCPC, Liam R. Brunham, MD, PhD, FRCPC Journal of Clinical Lipidology Volume 12, Issue 1, Pages (January 2018) DOI: /j.jacl Copyright © 2017 National Lipid Association Terms and Conditions
2
Figure 1 Prevalence of clinical or subclinical atherosclerotic cardiovascular disease (ASCVD) in individuals with damaging mutations in ABCA1 or APOA1. ∗P < .05. Journal of Clinical Lipidology , DOI: ( /j.jacl ) Copyright © 2017 National Lipid Association Terms and Conditions
3
Figure 2 Cholesterol efflux capacity (CEC) in individuals with damaging mutations in ABCA1 or APOA1. (A) Cholesterol efflux capacity. Results are presented as mean ± standard deviation. (B) Correlation between cholesterol efflux capacity and HDL-C levels. (C) Correlation between cholesterol efflux capacity and apoA-I levels. ∗P < .05. HDL-C, high-density lipoprotein cholesterol. Journal of Clinical Lipidology , DOI: ( /j.jacl ) Copyright © 2017 National Lipid Association Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.